ERBB2 and cancer: If proved in future clinical studies, the bifunctional activity of MEDICA in abrogating ErbB receptors and inhibiting mTORC1 activity (Fig. 7f) may offer a novel treatment mode for mTORC1-driven cancers in general and ErbB2 breast cancer in particular.